Regulatory FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients FDAThe U.S.Gene Therapy PlatformRead full story pharminent June 2, 2026 (Last updated: June 3, 2026) FDA The U.S. Gene Therapy Platform Read full story Post navigation Previous: ASCO: Merck overshadowed by upstart biotechs but TROP2 plans begin to pay offNext: ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
